Calico Provides Update on Fosigotifator in HEALEY ALS Platform …
Jan 6, 2025 · By activating eIF2B, fosigotifator could attenuate the ISR pathway and restore normal protein production in stressed nerve cells, potentially slowing the progression of ALS.
Sean M. Healey & AMG Center Announces Update in ALS Platform …
BOSTON – The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital today announced topline results from Regimen F of the HEALEY ALS Platform Trial evaluating …
Fosigotifator Fails to Meet End Points in HEALEY-ALS Platform Trial
Jan 7, 2025 · Topline data from regimen F of the HEALEY-ALS Platform trial revealed that fosigotifator (Calico Life Sciences), an investigational eIF2B activator, did not meet its primary …
Calico’s ALS drug trial fails to meet endpoints
Jan 9, 2025 · The study results found that fosigotifator did not significantly slow disease progression compared to the placebo group, and failed to improve respiratory function or …
ALS investigational therapies DNL343 and fosigotifator fail …
Jan 9, 2025 · The investigational oral therapies DNL343 and fosigotifator didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) compared with a …
ALS drug from Calico, anti-aging company, fails in study - STAT
Jan 6, 2025 · The company said Monday that fosigotifator failed to outperform placebo in slowing ALS, but it is testing it further.
ALS Trial Falls Short of Primary Goal - Calico – Medthority
Jan 9, 2025 · Calico Life Sciences LLC (Calico), an Alphabet company, announced initial topline results from Regimen F of the HEALEY ALS Platform Trial evaluating fosigotifator (ABBV CLS …
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests
Jan 7, 2025 · Massachusetts General Hospital found neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed disease progression, causing misses on the primary …
Calico Life Sciences Announces that Fosigotifator (ABBV-CLS …
Jun 7, 2024 · Calico and AbbVie are currently conducting a Phase 1b/2 trial of fosigotifator to evaluate the safety, tolerability, and pharmacokinetics of fosigotifator in participants diagnosed …
Google's anti-aging company just released 'disappointing' drug …
Jan 7, 2025 · Google’s (GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug. Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a …